Actuate Therapeutics, Inc. (NASDAQ:ACTU)
| Market Cap | $5.41M-96.4% |
| Revenue (ttm) | $0 |
| Net Income | -$18.47M+23.4% |
| EPS | -$0.78+46.9% |
| Shares Out | 24.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 629,804 |
| Open | $0.20 |
| Previous Close | $0.21 |
| Day's Range | $0.20 - $0.25 |
| 52-Week Range | $0.17 - $7.90 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | $21.00(+9220.91%) |
| Earnings Date | Mar 25, 2027 |
About ACTU
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
Actuate Therapeutics, Inc. Stock Analysis — InsiderScore
Actuate Therapeutics, Inc. scored higher than 52% of companies evaluated by InsiderBuying, and ranked 35th out of 102 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Actuate Therapeutics, Inc. bought $50.0K of stock across 1 purchase in the last 90 days, the largest of them $50.0K.
The average purchase added about 47% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 25, 2027Earnings report
$ACTU stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ACTU holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ACTU's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ACTU Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ACTU patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ACTU from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ACTU
| VTIVanguard Morningstar Total Stock Market ETF | $75.89K |
| VXFVanguard Extended Market ETF | $35.54K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $10.00K |
| IWCiShares Micro-Cap ETF | $7.42K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ACTU’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
-16.0 since Oct 29Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.01% |
Weight is the stock’s share of each fund’s holdings.
